REMISSION AFTER CAR T‐CELLS: DO PATIENTS RECOVER A NORMAL LIFE?

Introduction: CD19 CAR T-cells can induce prolonged remission in a significant number of patients with relapse/refractory (R/R) lymphoma. However, little is known about patients’ life after T-cell therapy. Here, we conducted prospective study to evaluate health-related quality (HRQol), as well physical, social and professional outcomes Methods: This was at the University Hospitals Rennes Toulouse (France). All adult R/R lymphoma treated were eligible. HRQol changes assessed using FACT-Lym questionnaire. Other questionnaires evaluated cognitive state (FACT-Cog), fatigue (FACT-Fatigue), anxiety depression (HAD scale), post-traumatic stress disorder (PTSD), sexuality (Vican). Questionnaires collected baseline (before leukapheresis), immediately before CAR-T infusion, 3 6 months infusion. Patients censored case relapse or death. Among 12 months, professional, sexual global information collected. Results: From March 2020 August 2022, 59 included (46 LBCL, 5 MCL, 8 FL). Median age 63 years (range, 19–78). axi-cel (N = 37), tisa-cel 18) brexu-cel 3). The median follow-up infusion 11 months. There 53 38 still respectively. score showed clinically relevant improvement HRQol, mean change from 10.9 points (95%CI 5.8; 16.1) 12.2 4.2; 20.1), subscale 5.9 2.9; 8.8) 4.7 0.2; 9.2), FACT-Cog did not show any change. HAD that 43% 24% presented baseline, respectively, versus 26% 7% Overall, PTSD (i.e., >44) 54.5% considered their back normal diagnosis); 68.2% satisfied life, 59.1% it normal; 54% felt less fit than lymphoma; 21/21 practicing physical activity resumed activity; 3/8 working population (n 10), 50% had returned work. Encore Abstract - previously submitted EHA 2023 Keywords: Aggressive B-cell non-Hodgkin lymphoma, Cellular therapies, Conflicts interests pertinent abstract F. Colin Consultant advisory role Gilead, Novartis A. Anota AMGEN, IPSEN, ASTRAZENECA, KITE-GILEAD Educational grants: KITE GILEAD L. Ysebaert AstraZeneca, Beigene, BMS/Celgene, Janssen, Gilead/Kite R. Houot Kite/Gilead Honoraria: Bristol Myers Squibb/Celgene, MSD, Kite/Gilead, Roche, Novartis, Janssen Moignet Kite,